The FDA Grand Rounds is an educational presentation that is webcast monthly to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute educational presentation is followed by questions from the audience. You can also view the presentation under Past Grand Rounds following the live webcast. #FDAGrandRounds.
Thursday, July 14, 2022
12:00 PM - 1:00 PM EST
About the Speakers
CAPT Brianna Skinner, DVM, MPH, DACLAM
Senior Regulatory Veterinarian
Office of Counterterrorism and Emerging Threats (OCET)
Food & Drug Administration (FDA)
Annamaria Castiglia, DVM
One Health Coordinator
Center of Veterinary Medicine (CVM)
Food and Drug Administration (FDA)
CAPT Brianna Skinner is a Commissioned Corps Officer in the U.S. Public Health Service currently assigned to the Office of Counterterrorism and Emerging Threats (OCET) at the U.S. Food and Drug Administration (FDA) as a Senior Regulatory Veterinarian. She serves as a co-lead for the operations of FDA’s One Health Steering Committee, as senior staff advisor for FDA’s Animal Welfare Council and as an animal model expert for the administration of policies to facilitate the availability of safe and effective medical countermeasures in OCET. Prior to transferring to the FDA, she worked at the Centers for Disease Control and Prevention leading clinical operations within the vivarium and consulting with principal investigators on animal care and use with infectious disease research. She earned her Doctor of Veterinary Medicine degree from Tuskegee University, her Master’s in Public Health from Benedictine University, and is board certified in laboratory animal medicine with the American College of Laboratory Animal Medicine.
Dr. Annamaria Castiglia is a Veterinary Medical Officer currently working for the Center of Veterinary Medicine (CVM) in the Office of the Director as the CVM One Health Coordinator. Prior to her position at FDA, she worked in Small Animal Practice and the Animal Health Industry both domestically and internationally. In 1999, she was relocated by Hoffman La Roche-Animal Health to Washington, D.C. to represent them on Capitol Hill. During that year she completed her Lobbying Training Programs in Washington, D.C. In 2005-2019, she joined the One Health Academy as the coordinator in Washington, D.C. and was a member of the One Health Academy Board of Directors. She earned her Doctor of Veterinary Medicine degree from Bologna University, in Bologna Italy. She also completed the following post graduate programs: small animal medicine at the Animal Medical Center, New York City, New York; food animal medicine at the University of Pennsylvania Veterinary College, and swine health and management at Michigan State University and Iowa State University.
About the Presentation
The One Health concept works at the interconnection of three domains: human, animal, and environmental health. One Health presents a more holistic view of the U.S. Food and Drug Administration's (FDA) mission. The FDA's efforts to improve health go beyond recognizing disease transmission through an isolated lens of human health and acknowledge human-animal interactions and associated environmental factors. The One Health concept's convergence already exists in the FDA's mission statement when considering the Agency's responsibilities and authorities. The Agency fulfills its mission to benefit both people and animals by ensuring the safety and efficacy of regulated products such as food or feed, drugs, devices, and human biologics. It regulates the manufacturing, marketing, and distribution of regulated products to ensure that safety and quality standards are met that benefit both people and animals. The Agency utilizes a multidisciplinary and multisectoral approach to gathering data that enhances more informed, evidence-based regulatory decisions when establishing standards and guidance. Last but not least, FDA coordinates regulatory pathway measures fostering the advancement of medical countermeasures that diagnose, prevent, protect, and treat conditions derived from intentional or unintentional emerging threats for chemical, biological, radiological, or nuclear materials. These threats hold no boundaries and can adversely impact people and animals alike. This presentation will describe the One Health concept and how it applies to FDA's regulatory mission. It will also explain FDA's application of the One Health concept in its regulatory activities.
For technical assistance please contact: Madison.Hanson@fda.hhs.gov
Past Grand Rounds
- Some Perspecitves on Data Science and Coronaviruses
- The Saga of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors
- MinION Sequencing of Foodborne Pathogens
- An Overview of Tattoo Ink Research at the National Center for Toxicological Research
- Challenges in Predicting the Environmental Exposure Concentration of Terrestrial Animal Drugs
- Development and Testing of Warnings for Tobacco Products: Scientific and Regulatory Considerations
- Closer to Zero
- The Development of Cellular-Level Structural and Functional Biomarkers of Eye Disease Enabled by Adaptive Optics
- Laboratory and Clinical Studies to Investigate Whether Ranitidine Converts to a Probable Carcinogen in Humans